(CSE: CBII-OTCQB: CBIIT) CEO Prad Sekar joined Steve Darling on Skype from London with news the company has been selected as an exclusive research technology platform for the UK’s largest medical cannabis Pilot – Project TWENTY21
Sekar told Proactive about that project and how CB2 will be involved.
CSE:CBII
Market: CSE
Market Cap: $9.6 m
Follow
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of CB2 Insights Inc. named herein, including the promotion by the Company of CB2 Insights Inc. in any Content on the Site, the Company receives...
FOR OUR FULL DISCLAIMER CLICK HEREMost read
Full interview: CB2 Insights announces key partnership with GL Brands for...
CB2 Insights ((CSE: CBII; OTCQB: CBIIF) CEO Prad Sekar joined Steve Darling from our Toronto studio to provide details the will begin a prospective trial with GL Brands that will assess the safety, efficacy and other health measures for patients using Green Lotus’ cannabidiol soft gel capsules...
on 12/17/2019
2 min read
Prev article
2 min read
